Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$44.89
$0.17(0.50%)
At close: 4:00 PM EST
$44.89
$0.17(0.50%)
Day’s Range― - ―
52-Week Range$33.76 - $57.57
Previous CloseN/A
Volume463.09K
Average Volume (3M)2.58M
Market Cap
$14.06B
Enterprise Value$11.12K
Total Cash (Recent Filing)$777.21M
Total Debt (Recent Filing)$169.54M
Price to Earnings (P/E)17.8
Beta0.87
Next Earnings
Aug 05, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding251,355,090
10 Day Avg. Volume2,511,858
30 Day Avg. Volume2,578,072
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$50.09Price Target Upside11.59% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)3.49
Revenue Forecast (FY)$2.60B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow And Cash ConversionEXEL's near parity of operating cash flow and free cash flow demonstrates durable cash conversion from operations. Strong FCF provides repeated internal funding for R&D, share repurchases, and milestone financing without reliance on external borrowing, supporting strategic optionality over the next several quarters.
High Profitability And MarginsExceptionally wide margins reflect a scalable small‑molecule commercial model and favorable product mix. Sustained high gross and EBIT margins create durable operating leverage, allowing the company to absorb higher clinical costs while funding pipeline programs and shareholder returns over a multi‑quarter horizon.
Commercial Momentum Of CABOMETYXConsistent TRx growth and rising market share signal durable demand and competitive positioning in RCC and related indications. A strengthening core franchise underpins predictable product revenues, strengthens negotiating leverage with partners/payers, and funds further development across multiple tumor types over coming quarters.
Bears Say
Rising Gross‑to‑Net DeductionsHigher gross‑to‑net deductions materially reduce realized product revenues per unit sold. If 340B, Medicare Part D discounts and copay assistance pressures persist, net sales growth and margin sustainability could be eroded, compressing long‑term cash generation and complicating revenue forecasting.
Pipeline/Regulatory Readout DependenceThe company's medium‑term growth trajectory depends on pivotal ZANZA trial outcomes and regulatory approvals. Delays, immature endpoints, or unfavorable readouts would materially limit new franchise expansion, heighten execution risk, and make revenue and earnings less predictable over the next 2–6 months.
Eroding Balance‑Sheet CushionA declining equity and asset base reduces balance‑sheet cushioning and can magnify adverse shocks. While leverage remains low today, shrinking equity can artificially boost ROE and constrain future capital flexibility if cash generation falters or if the company needs to scale spending for pivotal programs.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $33.76 and its highest was $57.57 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $14.06B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.762 by $0.108.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.85.
How many shares outstanding does Exelixis have?
Exelixis has 251,355,090 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.87 in its last earnings report, beating expectations of $0.762. Following the earnings report the stock price went up 9.635%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.09 (11.59% Upside)
$50.09 (11.59% Upside)
Blogger Sentiment
Bullish
EXEL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$50.09
▲(11.59% Upside)
Technical Analysis
Ownership Overview
3.52% Insiders
26.04% Mutual Funds
0.45% Other Institutional Investors
41.28% Public Companies and
Individual Investors